Meanwhile, LOXL2 silencing protects against Ang II-induced cardiac hypertrophy via inhibition of the EMT process and down-regulation of the TGF-β1/Smad3/NF-κB pathway. Here, LOXL2 is linked to cardiac hypertrophy.